Combination therapy with thalidomide, temozolomide and tamoxifen improves quality of life in patients with malignant astrocytomas

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2729-2736

  Rabbani, Golam ^a   Benzil, Deborah ^a   Wallam, Mohammed N ^a   Chen, Benjamin ^a   Hoang, Albert ^b   Kancherla, Ram ^a   Ahmed, Tauseef ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Adjuvant chemotherapy; Anaplastic astrocytoma; Antineoplastic combined chemotherapy protocol; Glioblastoma; Tamoxifen; Temozolomide; Thalidomide

Indexed keywords

ANTICOAGULANT AGENT; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASTROCYTOMA; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HUMAN; HYPERCOAGULATION; INFORMED CONSENT; KAPLAN MEIER METHOD; LEUKOCYTE; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SUPRATENTORIAL NEOPLASMS; TAMOXIFEN; THALIDOMIDE;

EID: 34547741718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML et al: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2(4): 619-622, 1996.
2. Prados MD and Levin V: Biology and treatment of malignant glioma. Semin Oncol 27(3 Suppl 6): 1-10, 2000.
3. Levine VA, Leibel SA and Gutin PH: Neoplasms of the central nervous system. In: DeVita VT, Hellman S and Rosenberg SA (eds.). Cancer: Principals and Practices of Oncology Philadelphia: J.B. Lippincott, Co, pp: 2022-2028, 1997.
4. Remer S and Murphy ME: The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin J Oncol Nurs 8(4): 368-376, 2004.
5. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL and Halperin EC: Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55(4): 992-999, 2003.
6. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D et al: Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101(9): 2079-2085, 2004.
7. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH et al: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103(4): 802-809, 2005.
8. Macdonald DR, Gaspar LE and Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27(5): 573-574, 1990.
9. Cairncross JG, Macdonald DR: Oligodendroglioma: a new chemosensitive tumor. J Clin Oncol 8(12): 2090-2091, 1990.
10. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U et al: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67(2): 121-132, 1983.
11. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303(23): 1323-1329, 1980.
12. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311): 1011-1018, 2002.
13. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4): 708-715, 2000.
14. Shapiro WR and Shapiro JR: Biology and treatment of malignant gliomas. Oncology 12(2): 233-240, 1998.
15. Brem H and Lawson HC: The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86(2): 197-199, 1999.
16. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D et al: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100(3): 472-479, 2004.
17. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH et al: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor(TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38(TP-38) for the treatment of malignant brain tumors. J Neurooncol 65(1): 27-35, 2003
18. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G et al: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54(4): 479-487, 2003.
19. Zunkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ et al: Quantification and pharmacokinetics of bloodbrain barrier disruption in humans. J Neurosurg 85(6): 1056-1065, 1996.
20. Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M et al: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37(1): 17-27; 28, 1995.
21. Neuwelt EA: Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neurosurgery 7(2): 204, 1980.
22. Chen B, Ahmed T, Mannancheril A, Gruber M and Benzil DL: Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas. Cancer 100(10): 2201-2207, 2004.
23. Rao RD, Uhm JH, Krishnan S and James CD: Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci 8: e270-280, 2003.
24. Rao RD and James CD: Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 31(5): 595-604, 2004.
25. Lefranc F, Brotchi J and Kiss R: Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23(10): 2411-2422, 2005.
26. Bouffet E, Mornex F, Jouvet A, Thiesse P, Mertens P, Helfre S et al: Assessment of procarbazine, vincristine and lomustine association(PCV protocol) in oligodendroglioma and mixed glioma. Bull Cancer 84(10): 951-956, 1997.
27. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P et al: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17(2): 645-650, 1999.
28. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V et al: Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 67(1-2): 191-200, 2004.
29. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005.
30. Brandes AA: Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. Abstracted from: Stupp R, Mason WP and van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. Cancer Treat Rev 31(7): 577-581, 2005.
31. Baltuch GH, Couldwell WT, Villemure JG and Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33(3): 495-501, 1993.
32. Baltuch GH, Dooley NP, Villemure JG and Yong VW: Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 22(4): 264-271, 1995.
33. Chamberlain MC and Kormanik PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 56(6): 703-708, 1999.
34. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J et al: A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3(7): 1109-1115, 1997.
35. Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T et al: Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 172(8): 5103-5109, 2004.
36. D'Amato RJ, Lentzsch S, Anderson KC and Rogers MS: Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 28(6): 597-601, 2001.
37. Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Pawlowska Z and Stepien H: Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 78(22): 2558-2563, 2006
38. Sridhar SS and Shepherd FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42(Suppl 1): S81-91, 2003.
39. Huncharek M and Muscat J: Treatment of recurrent high grade astrocytoma; results of a systematic review of 1, 415 patients. Anticancer Res 18(2B): 1303-1311, 1998.
40. Salcman M: Survival in glioblastoma: historical perspective. Neurosurgery 7(5): 435-439, 1980.
41. Salcman M, Scholtz H, Kaplan RS and Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34(2): 213-219, discussion 19-20, 1994
42. Salcman M, Kaplan RS, Ducker TB et al: Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytomas. Neurosurgery 10: 454-463, 1982.
43. Curren WJ et al: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Nat Cancer Inst 85: 704-710, 1993.
44. Quek ML and Penson DF: Quality of life in patients with localized prostate cancer. Urol Oncol 23(3): 208-215, 2005.
45. Boer AGEM, Lanschot JJB, Sandick JW, Hulscher JBF, Stalmeier PFM, Haes JCJM, Tilanus HW, Obertop H and Sprangers MAG: Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 22(20): 4202-4208, 2004.
46. Kornblith AB, Herndon JE II, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA and Holland JC: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J Clin Oncol 20(10): 2441-2452, 2002.
47. Beitz J, Gnecco C and Justice R: Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Nat Cancer Inst Monograph 20: 7-9, 1996.
48. Grossman SA and Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31: 635-644, 2004.
49. Carpentier A: Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol 4: 4-5, 2005.
50. Sipos L, Vitanovics D and Afra D: Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Ideggyogy Sz 57: 394-399, 2004.
51. Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr: Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54(2): 358-366, 66-67, 2004.
52. Liu G, Franssen E, Fitch MI and Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1): 110-115, 1997.
53. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P et al: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60(2): 353-357, 2004.
54. Hadaczek P, Mirek H, Berger MS and Bankiewicz K: Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J Neurosurg 102(2): 328-335, 2005.
55. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW et al: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56(6): 1243-1252, 52-53, 2005.
56. Sawaya RE and Ligon BL: Thromboembolic complications associated with brain tumors. J Neurooncol 22(2): 173-181, 1994.
57. Rossi R, Agnelli G, Taborelli P, Fioroni C, Zerbi D, Pattacini P et al: Local versus central assessment of venographies in a multicenter trial on the prevention of deep vein thrombosis in neurosurgery. Thromb Haemost 82(5): 1399-1402, 1999.
58. Skillman JJ, Collins RE, Coe NP, Goldstein BS, Shapiro RM, Zervas NT et al: Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery 83(3): 354-358, 1978.
59. Marras LC, Geerts WH and Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3): 640-646, 2000.
60. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F et al: Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33(10): 1592-1596, 1997.
61. Streiff MB, Segal J, Grossman SA, Kickler TS and Weir EG: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100(8): 1717-1723, 2004.
62. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A et al: First results from the International Breast Cancer Intervention Study(IBIS-I): a randomised prevention trial. Lancet 360(9336): 817-824, 2002.
63. Kaushal V, Kaushal GP, Melkaveri SN and Mehta P: Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2(2): 327-334, 2004.